ST段抬高型心肌梗死患者院内心脏骤停的危险因素
基于CCC-ACS项目40,670例STEMI患者,2.2%发生院内心脏骤停,其院内死亡率为53.0%,占住院死亡的55.0%。年龄≥75岁、女性、既往糖尿病、既往肾衰竭、院外心脏骤停、心率>100次/分、收缩压<90 mmHg及Killip IV级为预测因素;直接PCI、β受体阻滞剂和替格瑞洛与风险降低相关。
要点
- STEMI患者IHCA发生率2.2%,但IHCA患者院内死亡率高达53.0%。
- 年龄≥75岁、女性、既往糖尿病/肾衰竭、院外心脏骤停、心率>100、收缩压<90、Killip IV为预测因素。
- 直接PCI、β受体阻滞剂和替格瑞洛与IHCA风险降低独立相关。
核心结论
- STEMI患者中IHCA虽少见但死亡率高,多种可改变和不可改变因素与其发生相关,早期干预和合理药物治疗可能改善预后。
研究设计与样本
- 基于CCC-ACS项目(2014-2019)全国性数据库,对症状发作24小时内就诊的STEMI患者按住院期间是否发生IHCA进行分层分析。
主要发现
- 40,670例STEMI患者中2.2%(95%CI:2.1%-2.4%)发生IHCA。
- IHCA患者院内死亡率为53.0%(95%CI:49.7%-56.3%),IHCA占住院死亡的55.0%(95%CI:51.6%-58.4%)。
- 年龄≥75岁、女性、不吸烟、既往糖尿病、既往肾衰竭、院外心脏骤停、心率>100次/分、收缩压<90 mmHg和Killip IV级为IHCA预测因素。
- IHCA患者首次医疗接触后24小时内接受β受体阻滞剂和替格瑞洛及直接PCI的比例较低。
- 校正后直接PCI(aHR 0.82;95%CI 0.71-0.95)、β受体阻滞剂(aHR 0.63;95%CI 0.47-0.86)和替格瑞洛(aHR 0.57;95%CI 0.42-0.76)与IHCA风险降低相关。
临床怎么用
- 对STEMI患者应识别IHCA高危因素(如年龄≥75岁、女性、既往糖尿病/肾衰竭、院外心脏骤停、心率>100次/分、收缩压<90 mmHg、Killip IV级)并加强监测。
- 在无禁忌情况下,尽早使用β受体阻滞剂和替格瑞洛,并尽早行直接PCI,可能降低IHCA风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In-hospital cardiac arrest (IHCA) is one of the most deleterious complications of ST-segment elevation myocardial infarction (STEMI). OBJECTIVES: We systematically analyzed the clinical characteristics of STEMI patients with IHCA, as well as predictors and treatments associated with risk of IHCA, using a nationwide database. METHODS: In the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome) project (2014-2019), we stratified patients presenting with STEMI within 24 hours after symptom onset according to IHCA or no IHCA during the index hospitalization. We analyzed patients' clinical characteristics, mortality, and independent correlates of IHCA. RESULTS: Of 40,670 STEMI patients, 2.2% (95% CI: 2.1%-2.4%) experienced IHCA. Among IHCA patients, the in-hospital mortality was 53.0% (95% CI: 49.7%-56.3%). IHCA represents 55.0% (95% CI: 51.6%-58.4%) of inpatient deaths. Age ≥75 years, female, nonsmoker, prior diabetes mellitus, prior renal failure, out-of-hospital cardiac arrest, heart rate >100 beats/min, systolic blood pressure <90 mm Hg, and Killip IV were identified as predictors of IHCA. IHCA patients were less likely to receive β-blockers and ticagrelor during the first 24 hours after first medical contact and were less likely to undergo primary percutaneous coronary intervention. After adjustment, primary percutaneous coronary intervention (adjusted HR: 0.82; 95% CI: 0.71-0.95), β-blockers (adjusted HR: 0.63; 95% CI: 0.47-0.86), and ticagrelor (adjusted HR: 0.57; 95% CI: 0.42-0.76) were associated with a reduced risk of IHCA. CONCLUSIONS: IHCA is rare in STEMI but is associated with high mortality. Multiple modifiable and unmodifiable factors are associated with its occurrence, suggesting that early intervention and rational drug treatment may improve its prognosis. (CCC Project- Acute Coronary Syndrome; NCT02306616).
引用
- Gong, Yan, Wang, et al. Risk Factors for In-Hospital Cardiac Arrest in Patients With ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2022. PMID: 36328690. doi:10.1016/j.jacc.2022.08.797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。